Lab Sciences
Top stories summarized by our editors
11/14/2018

A study found that hepatitis C viral remission rates were high among people who injected drugs even when their adherence to treatment with sofosbuvir/velpatasvir was imperfect. "Active and ongoing drug use should not be used as a justification to deny treatment to patients," Dr. Elana Rosenthal said at The Liver Meeting 2018.

11/14/2018

Unum Therapeutics said it will report on data from an early-stage trial of its candidate ACTR707, in combination with Roche Holding's Rituxan, or rituximab, for patients with relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma at a meeting of the American Society of Hematology. Enrollment in the study is expected to be completed next year.

Full Story:
Seeking Alpha
11/13/2018

Dr. Joshua Bauml said liquid biopsies have the potential to be an alternative to tissue biopsies in assessing resistance to cancer treatments. "We draw blood and request urine samples from our patients all the time, and the ability to test this serially is very appealing when we consider the fact that resistance develops over time," Bauml said at the 36th Annual Chemotherapy Foundation Symposium.

11/13/2018

Universal screening for hepatitis C virus infection is more cost-effective and efficient than risk-based screening in pregnant women, data show.

More Summaries:
HCV
11/13/2018

Laboratories adopting immunoassays for lipoprotein(a), which are designed to identify individuals at increased risk of cardiovascular disease, should determine providers' expectations on the targeted patient population and on guidelines for Lp(a) levels. Labs and clinicians should be aware of racial/ethnic differences in Lp(a) levels, particularly in African-Americans.

11/13/2018

A Series A financing round has pulled in about $3.7 million for Canada-based medical technology firm Rna Diagnostics. Part of the proceeds will be used to commercialize the company's RNA disruption assay.

More Summaries:
Rna Diagnostics
11/12/2018

Chembio Diagnostic Systems' DPP Ebola Antigen System is the second rapid antigen fingerstick test granted emergency use authorization by the FDA to detect the Ebola virus in patients. It is the first that uses a mobile battery-operated reader, which allows it to provide diagnostic results outside of laboratories.

11/12/2018

Almost 500,000 uninsured people in five states are expected to gain access to Medicaid coverage following the midterm elections, advocates say. Three states voted to expand Medicaid eligibility, while two others elected governors who have promised to support state legislation expanding their programs.

Full Story:
Kaiser Health News
11/12/2018

Cases of Ebola virus infection in the Democratic Republic of Congo have reached 319, with 198 people dead, making it the largest outbreak in the country's history. "The risk of the outbreak spreading to other provinces in the Democratic Republic of the Congo, as well as to neighboring countries, remains very high," the World Health Organization said.

11/12/2018

An international panel of medical and academic experts identified a range of priority issues related to toxicity assessment in clinical trials of treatments for hematologic conditions and defined potential solutions. The commission included toxicities unique to hematopoietic stem cell transplantation among the issues, and the recommendations were reported in The Lancet Haematology.